E. Ohman J or Asset Management AB Buys 500 Shares of Illumina, Inc. (NASDAQ:ILMN)

E. Ohman J or Asset Management AB grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 6,965 shares of the life sciences company’s stock after purchasing an additional 500 shares during the period. E. Ohman J or Asset Management AB’s holdings in Illumina were worth $931,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. Cetera Investment Advisers increased its holdings in Illumina by 25.8% during the 2nd quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock worth $1,919,000 after purchasing an additional 3,767 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Illumina by 31.1% in the third quarter. GAMMA Investing LLC now owns 2,919 shares of the life sciences company’s stock valued at $381,000 after acquiring an additional 692 shares in the last quarter. Azzad Asset Management Inc. ADV grew its holdings in shares of Illumina by 8.1% in the third quarter. Azzad Asset Management Inc. ADV now owns 4,235 shares of the life sciences company’s stock valued at $552,000 after acquiring an additional 317 shares in the last quarter. Diversified Trust Co bought a new position in shares of Illumina in the third quarter valued at approximately $243,000. Finally, Axiom Advisory LLC grew its holdings in shares of Illumina by 3.2% in the third quarter. Axiom Advisory LLC now owns 6,528 shares of the life sciences company’s stock valued at $805,000 after acquiring an additional 204 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Up 0.4 %

ILMN opened at $124.68 on Thursday. The stock has a market cap of $19.77 billion, a PE ratio of -12.52 and a beta of 1.10. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The business’s fifty day simple moving average is $138.19 and its 200 day simple moving average is $135.50.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same period last year, the firm earned $0.33 earnings per share. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. As a group, research analysts expect that Illumina, Inc. will post 4.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ILMN shares. Leerink Partners upped their target price on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. HSBC raised Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a report on Thursday, October 17th. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a report on Thursday, October 17th. UBS Group increased their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Robert W. Baird increased their price objective on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $164.84.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.